30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis

Saved in:
Bibliographic Details
Main Authors: Enrique M. Ocio, Aurore Perrot, Philippe Moreau, Maria‐Victoria Mateos, Sara Bringhen, Joaquín Martínez‐López, Lionel Karlin, Song‐Yau Wang, Corina Oprea, Yi Li, Ercem Kodas, Jesus San‐Miguel
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:HemaSphere
Online Access:https://doi.org/10.1002/hem3.70041
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850160967931920384
author Enrique M. Ocio
Aurore Perrot
Philippe Moreau
Maria‐Victoria Mateos
Sara Bringhen
Joaquín Martínez‐López
Lionel Karlin
Song‐Yau Wang
Corina Oprea
Yi Li
Ercem Kodas
Jesus San‐Miguel
author_facet Enrique M. Ocio
Aurore Perrot
Philippe Moreau
Maria‐Victoria Mateos
Sara Bringhen
Joaquín Martínez‐López
Lionel Karlin
Song‐Yau Wang
Corina Oprea
Yi Li
Ercem Kodas
Jesus San‐Miguel
author_sort Enrique M. Ocio
collection DOAJ
format Article
id doaj-art-6f512f0c1c04412f938e07f19b14f6ba
institution OA Journals
issn 2572-9241
language English
publishDate 2024-11-01
publisher Wiley
record_format Article
series HemaSphere
spelling doaj-art-6f512f0c1c04412f938e07f19b14f6ba2025-08-20T02:23:00ZengWileyHemaSphere2572-92412024-11-01811n/an/a10.1002/hem3.7004130‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysisEnrique M. Ocio0Aurore Perrot1Philippe Moreau2Maria‐Victoria Mateos3Sara Bringhen4Joaquín Martínez‐López5Lionel Karlin6Song‐Yau Wang7Corina Oprea8Yi Li9Ercem Kodas10Jesus San‐Miguel11Servicio de Hematología y Hemoterapia, Hospital Universitario Marqués de Valdecilla University Hospital (IDIVAL) Universidad de Cantabria Santander SpainService d'Hématologie, CHU de Toulouse, IUCT‐O Université de Toulouse Toulouse FranceDepartment of Hematology University of Nantes Nantes FranceDepartment of Hematology University Hospital of Salamanca and Cancer Research Center (IBMCC‐CSICUSAL) Salamanca SpainDepartment of Onco‐Ematologia e Myeloma Multiplo, SSD Clinical Trials AOU Città della Salute e della Scienza di Torino ItalyDepartment of Hematology Hospital Universitario 12 de Octubre, CNIO, Universidad, Complutense de Madrid SpainService d'Hématologie Clinique, Hôpital Lyon Sud Hospices Civils de Lyon Pierre‐Bénite FranceDepartment of Hematology and Oncology University of Leipzig Leipzig GermanyResearch and Development, Sanofi Vitry‐sur‐Seine FranceResearch and Development, Sanofi Bejing ChinaResearch and Development, Sanofi Vitry‐sur‐Seine FranceDepartment of Clinical and Translational Medicine University of Navarra (CCUN), Center for Applied Medical Research (CIMA), IDISNA, CIBERONC Pamplona Spainhttps://doi.org/10.1002/hem3.70041
spellingShingle Enrique M. Ocio
Aurore Perrot
Philippe Moreau
Maria‐Victoria Mateos
Sara Bringhen
Joaquín Martínez‐López
Lionel Karlin
Song‐Yau Wang
Corina Oprea
Yi Li
Ercem Kodas
Jesus San‐Miguel
30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
HemaSphere
title 30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
title_full 30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
title_fullStr 30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
title_full_unstemmed 30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
title_short 30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
title_sort 30 minute infusion of isatuximab in patients with newly diagnosed multiple myeloma results of a phase 1b study analysis
url https://doi.org/10.1002/hem3.70041
work_keys_str_mv AT enriquemocio 30minuteinfusionofisatuximabinpatientswithnewlydiagnosedmultiplemyelomaresultsofaphase1bstudyanalysis
AT auroreperrot 30minuteinfusionofisatuximabinpatientswithnewlydiagnosedmultiplemyelomaresultsofaphase1bstudyanalysis
AT philippemoreau 30minuteinfusionofisatuximabinpatientswithnewlydiagnosedmultiplemyelomaresultsofaphase1bstudyanalysis
AT mariavictoriamateos 30minuteinfusionofisatuximabinpatientswithnewlydiagnosedmultiplemyelomaresultsofaphase1bstudyanalysis
AT sarabringhen 30minuteinfusionofisatuximabinpatientswithnewlydiagnosedmultiplemyelomaresultsofaphase1bstudyanalysis
AT joaquinmartinezlopez 30minuteinfusionofisatuximabinpatientswithnewlydiagnosedmultiplemyelomaresultsofaphase1bstudyanalysis
AT lionelkarlin 30minuteinfusionofisatuximabinpatientswithnewlydiagnosedmultiplemyelomaresultsofaphase1bstudyanalysis
AT songyauwang 30minuteinfusionofisatuximabinpatientswithnewlydiagnosedmultiplemyelomaresultsofaphase1bstudyanalysis
AT corinaoprea 30minuteinfusionofisatuximabinpatientswithnewlydiagnosedmultiplemyelomaresultsofaphase1bstudyanalysis
AT yili 30minuteinfusionofisatuximabinpatientswithnewlydiagnosedmultiplemyelomaresultsofaphase1bstudyanalysis
AT ercemkodas 30minuteinfusionofisatuximabinpatientswithnewlydiagnosedmultiplemyelomaresultsofaphase1bstudyanalysis
AT jesussanmiguel 30minuteinfusionofisatuximabinpatientswithnewlydiagnosedmultiplemyelomaresultsofaphase1bstudyanalysis